Which Treatments for Myasthenia Gravis Better Improve HRQoL Outcomes?

Among the new targeted therapies for generalized myasthenia gravis (MG), efgartigimod was found to improve health-related quality of life (HRQoL) outcomes, according to study results presented at the 2023 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting, held from November 1 to 4 in Phoenix, Arizona.

Researchers conducted a Bayesian network meta-analysis to compare the newer treatments for generalized MG in terms of HRQoL outcomes.

The researchers analyzed published data from 4 randomized placebo-controlled phase 3 trials. To assess outcomes, the researchers used changes in HRQoL outcomes, European QOL 5 Dimensions visual analog scale (EQ-5D VAS), and MG QOL revised (MG-QoL 15r) questionnaires.

Findings of the meta-analysis showed that treatment with efgartigimod vs ravulizumab resulted in improved EQ-5D VAS (mean difference, 10.39; 95% credible interval [Crl], 2.39-18.31) and MG-QoL 15r scores (-3.29; 95% Crl, -6.01 to -0.61).

Efgartigimod was also superior to zilucoplan on the EQ-5D VAS scale (8.50; 95% Crl, 0.66-16.48); however, improvements in MG-QoL 15r were not significantly different between the 2 treatments.

Improvements on the EQ-5D VAS and MG-QoL 15r scales were not significantly different between treatment with efgartigimod and rozanolixizumab 7 and 10 mg.

The researchers concluded, “The results suggested efgartigimod was associated with greater degree of improvement in EQ-5D VAS (compared to ravulizumab and zilucoplan) and MG-QoL15r (compared to ravulizumab) scores in patients with gMG [MG].”